Other Mutations: KEAP1

NCT05039801: IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors

NCT05039801
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NF1/2, KEAP1, STK11
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one line of therapy for advanced stage disease and be refractory or ineligible to available existing therapy(ies) known to provide clinical benefit
Exclusions: Patients with symptomatic central nervous system metastasis(es) that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT05039801

NCT03872427: Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study

NCT03872427
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NF1/2, KEAP1, STK11
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active, untreated, symptomatic brain metastases – see trial for details
https://ClinicalTrials.gov/show/NCT03872427

Up ↑